To our valued patients, community members and colleagues,

We wish to thank you for your ongoing support and loyal partnership.

For 100 years, it has been the privilege of Salem Health to provide cancer services to the greater Salem community. And we continue to make great strides forward.

In the last five years, with the creation of Salem Cancer Institute, we have made significant contributions in providing cancer care to the community. We have treated more than 1,500 cancer patients per year, offering advanced surgical, radiation and chemotherapy care. In doing so, we have matched – and often exceeded – the national average survival rates.

We have also added care coordination by experienced oncology nurses and social workers, recruited more than 20 physicians across the spectrum of cancer care, provided medical assistance programs for uninsured patients and created a palliative care program.

To ensure that we continually provide high quality care, we have held more than 50 tumor board reviews annually and have forged a relationship with Oregon Health & Science University, an important regional cancer research institution.

While we celebrate these achievements, we know there’s much more work to be done. Our vision is to be recognized as the leading patient-centered community program on the West Coast.

To accomplish this goal, we are committed to making Salem Cancer Institute a patient’s best choice for care, based on our ability to:

- Attract skilled physicians and specialists as the foundation of clinical excellence,
- Offer the most advanced and fully integrated treatment technology,
- Achieve the highest survival rates while focusing on quality of life,
- Provide comprehensive services so that patients can receive support close to home, and
- Rate in the top percentile in patient satisfaction and service quality.

As research leads to more exciting breakthroughs and as clinicians develop new ways of treatment, we may in our lifetime build a bridge that leads to a cure. In the meantime, we will continue to support the needs of our patients and community at every point on the cancer care journey.

Sincerely,

Nancy Boutin, M.D.
Medical Director,
Salem Cancer Institute

Steven Taylor
Director,
Salem Cancer Institute

At Salem Cancer Institute, our physicians and staff have provided cancer care for 100 years and advanced oncology care to the Willamette Valley for more than 35 years.

As a program of Salem Health, the institute includes leading physicians, clinics and community organizations. We offer the latest clinical care, technology and education programs to the Salem area and beyond.

Increasing capabilities
Salem Cancer Institute brings together the skills and capabilities of Salem Health and the physicians in the Willamette Valley. Many of Oregon’s most highly skilled healthcare providers choose to live and work in this area. Our capabilities continue to increase as new physicians join our teams and as we invest in state-of-the-art technology.

As a result, patients at Salem Cancer Institute receive the most up-to-date cancer therapies in a supportive environment with coordinated care and services. In addition, our affiliation with the OHSU Knight Cancer Institute gives our patients direct access to advanced clinical services in an academic center environment.

Highly skilled oncology teams
Salem Cancer Institute brings highly skilled physicians together with registered oncology nurses, technicians, therapists and other staff. Experts from every medical discipline form interdisciplinary teams to ensure the best cancer care based on their combined knowledge and skill.

We have developed tumor site committees in accordance with best practice guidelines from the Advisory Board Oncology Roundtable. The physicians meet to discuss cases at breast, gastrointestinal, thoracic and neurological tumor site committees. The goal is to streamline, improve and better coordinate medical care and patient outcomes. This work has earned Salem Cancer Institute national recognition: for example, recently the Breast Committee played a crucial role in earning our distinction as a nationally accredited breast center – only the third institution in Oregon to receive such designation.

Our tumor site committees:

GI Cancer
Bob Ponec, M.D., Chairman

Breast Cancer
Beth Dayton, M.D., Chairman

Thoracic Cancer
Everett Mozell, M.D., Chairman

Neurological Cancer
Maurice Collada, M.D., Chairman
Working together for our patients: A winning team

Salem Cancer Institute provides comprehensive cancer therapies and services. Our expertly trained surgeons, medical oncologists and radiation oncologists collaborate with other physician diagnosticians to provide advanced and specialized care across a wide spectrum of cancer services. The vast majority of our patients can be treated here with therapies and outcomes equivalent to the nation’s largest cancer centers. Other patients receive treatment through our seamless affiliation with OHSU Knight Cancer Institute.

As part of one of the busiest hospitals in the state, we treat a very high volume of patients, allowing us to further develop our specialty oncology services and offer expertise similar to any major metropolitan area. Most of our physicians and specialists are board certified and fellowship trained, and have been working together to coordinate cancer care and create exemplary outcomes for more than 15 years.

A statewide leader in cancer technology

Our commitment to quality includes providing advanced technology in the fight against cancer.

Advanced radiation therapy options

Trilogy® RapidArc and Stereotactic Radiosurgery

Salem Cancer Institute has one of just three Trilogy systems in Oregon. This addition to our radiation oncology capabilities uses state-of-the-art external beam radiation therapy that conforms to tumors precisely, sparing healthy tissue and nearby organs. The Trilogy system’s precision allows higher dose rates for more effective treatment and shorter treatment times. Because the therapy is completed in fewer sessions than previously possible, patient comfort is significantly increased.

Stereotactic radiosurgery is used to treat complicated lung, liver, and pancreatic lesions and tumors close to the spinal cord or brainstem that might otherwise be inoperable.

TomoTherapy® treatment system

TomoTherapy combines intensity-modulated radiation therapy with CT image guidance. With pinpoint accuracy, it effectively treats hard-to-reach tumors of the prostate, brain, spine and other areas. TomoTherapy can also treat metastatic disease, recurrence and secondary cancers. With its integrated advanced imaging, TomoTherapy helps protect healthy tissue and reduce side effects. Salem Cancer Institute is one of just three centers in Oregon offering TomoTherapy.

High-dose radiation (HDR) suite

Our newly remodeled high-dose radiation suite is a dedicated environment for brachytherapy, primarily for gynecologic malignancies. We also offer high-dose radiation as an advanced alternative treatment for certain breast cancers.

Minimally invasive surgery

da Vinci® robotic surgical system

The da Vinci system is a minimally invasive surgical option available to treat prostate and gynecologic cancers. Six urologists and one gynecologic oncologist have da Vinci privileges at Salem Health. The da Vinci system combines the latest technology with individual surgeon expertise.

State-of-the-art surgery suites, anesthesia care

Our surgical suites have been completely updated to deliver the highest quality care and accommodate our growing surgical volumes.

All of our anesthesia providers are physicians and are members of the Oregon Anesthesiology Group. Our Anesthesiologist-in-Charge program serves as a model for leadership in the surgical services area.

Surgery
15 general surgeons, many with special interest and advanced training in cancer care
2 gynecologic oncologists
5 neurosurgeons
6 otolaryngologists
8 urologists, six of them practicing robotic surgery
1 cardiothoracic surgeon specializing in cancer care
4 plastic surgeons

Radiation Oncology
6 radiation oncologists, covering a full range of cancer specialties that include radiosurgery, HDR implants, IMRT, IGRT and 3D treatments.

Diagnosticians
10 gastroenterologists
8 pathologists
7 pulmonologists
18 radiologists

Medical Oncology
5 medical oncologists, board certified in internal medicine, hematology and oncology. Three have clinical associate professor appointments at OHSU, where they are involved in teaching and research.

Palliative Medicine
3 palliative care physicians
Exemplary outcomes

The combination of highly skilled physicians and specialists, comprehensive treatment options, significant volume and advanced technology have made Salem Cancer Institute a leader in treatment outcomes in Oregon and the western United States.

As a key quality measure, survival rates at Salem Cancer Institute are higher or statistically comparable to survival rates at the major cancer institutes on the West Coast and nationally.

The Commission on Cancer (CoC) National Cancer Data Base performance rates for breast cancer treatment show Salem Cancer Institute delivering the accepted standard of care – radiation within a year of breast-conserving surgery – 99 percent of the time.

This is significantly better than overall United States rates, in which women received this treatment 78 percent of the time. For Oregon hospitals, the statewide average rate is 88 percent.

In a second key area, combination chemotherapy, Salem Cancer Institute delivered the accepted standard of care 100 percent of the time. Nationally the rate is 78 percent; statewide, the accepted standard is met 87 percent of the time.

The chart below summarizes key data points from the National Cancer Data Base (NCDB). In every key measurement, Salem Cancer Institute performs at levels significantly above the national and statewide average.

The chart below summarizes key data points from the National Cancer Data Base (NCDB). In every key measurement, Salem Cancer Institute performs at levels significantly above the national and statewide average.

<table>
<thead>
<tr>
<th>Cancer Program Practice Profile Reports</th>
<th>Estimated performance rates, 2008</th>
<th>Salem Cancer Institute</th>
<th>All CoC-approved programs*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast cancer: Select measures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiation therapy is administered within one year of diagnosis for women under age 70 receiving breast-conserving surgery for breast cancer (B/C/RT)</td>
<td>98.9%</td>
<td>78.1%</td>
<td></td>
</tr>
<tr>
<td>Combination chemotherapy is considered or administered within four months of diagnosis for women under age 70 with AJCC T1c No Mo, or Stage II or III ER+ and PR+ breast cancer [MAC]</td>
<td>100%</td>
<td>78.2%</td>
<td></td>
</tr>
<tr>
<td>Tamoxifen or third-generation aromatase inhibitor is considered or administered within one year of diagnosis for women with AJCC T1c No Mo, or Stage II or III ER+ and/or PR+ positive breast cancer [HT]</td>
<td>97.3%</td>
<td>64.2%</td>
<td></td>
</tr>
<tr>
<td><strong>Colon cancer: Select measures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant chemotherapy is considered or administered within four months of diagnosis for patients under age 80 with AJCC Stage III (lymph node positive) colon cancer [ACT]</td>
<td>100%</td>
<td>81.6%</td>
<td></td>
</tr>
<tr>
<td>At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (aCMRP)</td>
<td>87.5%</td>
<td>79.6%</td>
<td></td>
</tr>
<tr>
<td>Radiation therapy is considered or administered within six months of diagnosis for patients under age 80 with clinical or pathologic AJCC T1a No Mo or Stage III resectable surgical resection for rectal cancer [AdjRT]</td>
<td>100%</td>
<td>85.9%</td>
<td></td>
</tr>
</tbody>
</table>

*Rates computed based on data directly reported to the NCDB using specifications endorsed by the National Quality Forum.

Salem Cancer Institute’s breast conservation rate is substantially higher than the national average.

Five-year observed survival rates

The Commission on Cancer also tracks survival rates by tumor site and cancer stage, compiling data from 563 CoC-approved facilities and 257 teaching/research facilities nationwide. The comprehensive and impartial data gathered for this effort shows survival rates at Salem Cancer Institute to be comparable to or higher than the national average.

Salem Cancer Institute vs. CoC Comprehensive Community Centers and teaching/research facilities

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Survival Rate</th>
<th>Salem Cancer Institute</th>
<th>CoC Comprehensive Community Centers</th>
<th>Teaching/research facilities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast Cancer</strong></td>
<td></td>
<td>63%</td>
<td>55%</td>
<td>43%</td>
</tr>
<tr>
<td><strong>Colon Cancer</strong></td>
<td></td>
<td>98%</td>
<td>85%</td>
<td>72%</td>
</tr>
<tr>
<td><strong>Lung Cancer</strong></td>
<td></td>
<td>90%</td>
<td>75%</td>
<td>60%</td>
</tr>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td>100%</td>
<td>90%</td>
<td>80%</td>
</tr>
</tbody>
</table>

Exemplary outcomes are a direct reflection of our team approach to cancer care.
Breast Center awarded national accreditation
In 2010, Salem Cancer Institute became one of only three cancer centers in the state to receive the distinction of being a nationally accredited breast center. The distinction, from the National Accreditation Program for Breast Centers (NAPBC), is given only to centers that commit to providing the best in breast cancer diagnosis and treatment.

During the survey, Salem Cancer Institute demonstrated compliance with NAPBC standards for treating women with the full spectrum of breast disease. Standards include proficiency in leadership, clinical management, research, community outreach, professional education and quality improvement.

Receiving care at a NAPBC-accredited center such as Salem Cancer Institute ensures patients access to comprehensive care, including a full range of state-of-the-art services.

Clinical Trials scores among the top centers worldwide
Salem Health’s Clinical Trials department received a perfect score during our 2010 audit by the Radiation Therapy Oncology Group (RTOG). RTOG is a national cooperative group affiliated with the American College of Radiology and primarily funded by the National Cancer Institute.

Of 240 RTOG site audits worldwide, just 10 centers received perfect scores. This places our Clinical Trials program in the top 7 percent of RTOG programs.

Gynecologic oncology services
After 16 months of planning, Salem Cancer Institute reinstated the GYN/ONC program in the summer of 2010. OHSU’s Dr. Elizabeth Munro, who completed her residency in OB/GYN at Stanford and her fellowship in GYN/ONC at Massachusetts General Hospital, sees patients and performs surgery two days a week in Salem. Through the first four months of operation, 366 patients were seen in clinic. The program performed 38 surgeries and 13 office procedures.

Interdisciplinary teams of physicians contributed to the reinstallation of this program, including the OHSU Affiliation Steering Committee, General Surgery Section, Trauma and Acute Care Surgery Services (TRACS), medical oncologists, radiation oncologists and OB/GYN physicians. Patients are cared for in cooperation between Dr. Munro and referring OB/GYN physicians who often assist on surgical cases. As the program grows, clinic days and surgical availability will be increased.

Southwest Oncology Group commends Salem Clinical Trials
The Southwest Oncology Group, one of the largest cooperative groups for cancer clinical trials in the United States, commended Salem Cancer Institute in its most recent audit for a high level of organization, high-quality work and strength in quality patient care.

Advancing the quality of cranial radiosurgery
Researchers at Salem Cancer Institute and OHSU Knight Cancer Institute investigated the use of Intensity-Modulated Arc Therapy (IMAT), the latest rapid arc technology for cranial radiosurgery. Their study found that IMAT significantly improves the dose conformity and lowers toxicity, compared to conventional approaches. IMAT plans produce higher conformity, steeper gradient and lower dose to organs-at-risk, while having increased monitor units and computation time. IMAT may be a superior alternative for cranial radiosurgery. The study will be accepted by the International Stereotactic Radiosurgery Society at their meeting in Paris in May 2011.

Major grant expands palliative care services
Salem Health received a $250,000 grant from The Regence Foundation in 2010 to support palliative care services at Salem Hospital. The largest grant awarded to Salem Health to date, it’s part of The Regence Foundation’s Sojourns program to promote hospital- and community-based palliative care services. Through Sojourns, the foundation aims to foster best practices, leadership and collaboration that help people with life-threatening and incurable illness to access quality palliative care in their own communities.

In February 2010, Salem Health received a planning grant of $17,600 to prepare the palliative care department to apply for this implementation grant. In addition, $85,000 was received from The Salem Hospital Foundation to launch the program.

Collaboration with OHSU
Since 2008, Salem Cancer Institute and OHSU Knight Cancer Institute have cooperated to improve care for people with cancer across Oregon. This collaboration assures that patients have access to any level of care, including subspecialty care and clinical trials. Salem Cancer Institute patients routinely take part in trials for breast, prostate and colon cancer and recently have been enrolling in the OHSU tissue registry for the enhancement of personalized medicine.

In addition, Salem Cancer Institute patients can receive genetic counseling services without leaving the area. The number of patients utilizing this service has more than tripled since the program’s inception and continues to grow.

Our shared electronic records enhance communication between care teams. Salem Cancer Institute physicians participate in joint medical education, further raising our standards of clinical care.

Oncology symposiums
As part of our commitment to continually increase the quality of cancer care in the Willamette Valley, Salem Cancer Institute, in partnership with OHSU Knight Cancer Institute, has led the way in developing a series of oncology symposiums, providing high-quality continuing education and allowing cancer specialists to share expertise in a collegial setting. The symposiums are well attended and have attracted physicians from a widening area to discuss clinical care, research and outcomes.

The success of the symposiums has prompted others to join in, including the Lower Columbia Regional Cancer Center. Symposia have been held on breast, prostate, lung and gastrointestinal tract malignancies.

Highlights
Salem Health’s Clinical Trials department received a perfect score during our 2010 audit by the Radiation Therapy Oncology Group (RTOG). RTOG is a national cooperative group affiliated with the American College of Radiology and primarily funded by the National Cancer Institute.

Of 240 RTOG site audits worldwide, just 10 centers received perfect scores. This places our Clinical Trials program in the top 7 percent of RTOG programs.

Salem Health received a $250,000 grant from The Regence Foundation in 2010 to support palliative care services at Salem Hospital. The largest grant awarded to Salem Health to date, it’s part of The Regence Foundation’s Sojourns program to promote hospital- and community-based palliative care services.

Researchers at Salem Cancer Institute and OHSU Knight Cancer Institute investigated the use of Intensity-Modulated Arc Therapy (IMAT), the latest rapid arc technology for cranial radiosurgery. Their study found that IMAT significantly improves the dose conformity and lowers toxicity, compared to conventional approaches. IMAT plans produce higher conformity, steeper gradient and lower dose to organs-at-risk, while having increased monitor units and computation time. IMAT may be a superior alternative for cranial radiosurgery.

In February 2010, Salem Health received a planning grant of $17,600 to prepare the palliative care department to apply for this implementation grant. In addition, $85,000 was received from The Salem Hospital Foundation to launch the program.

Collaboration with OHSU
Since 2008, Salem Cancer Institute and OHSU Knight Cancer Institute have cooperated to improve care for people with cancer across Oregon. This collaboration assures that patients have access to any level of care, including subspecialty care and clinical trials. Salem Cancer Institute patients routinely take part in trials for breast, prostate and colon cancer and recently have been enrolling in the OHSU tissue registry for the enhancement of personalized medicine.

In addition, Salem Cancer Institute patients can receive genetic counseling services without leaving the area. The number of patients utilizing this service has more than tripled since the program’s inception and continues to grow.

Our shared electronic records enhance communication between care teams. Salem Cancer Institute physicians participate in joint medical education, further raising our standards of clinical care.

Oncology symposiums
As part of our commitment to continually increase the quality of cancer care in the Willamette Valley, Salem Cancer Institute, in partnership with OHSU Knight Cancer Institute, has led the way in developing a series of oncology symposiums, providing high-quality continuing education and allowing cancer specialists to share expertise in a collegial setting. The symposiums are well attended and have attracted physicians from a widening area to discuss clinical care, research and outcomes.

The success of the symposiums has prompted others to join in, including the Lower Columbia Regional Cancer Center. Symposia have been held on breast, prostate, lung and gastrointestinal tract malignancies.

ATTRACTING TOP SPECIALISTS | Radiation Oncology
Tasha McDonald, M.D.
Dr. McDonald is a radiation oncologist and received her medical degree from the OHSU School of Medicine, where she was chief resident in radiation oncology and was awarded a research fellowship in radiation oncology. Dr. McDonald has special training in stereotactic radiosurgery for treating difficult brain cancers and stereotactic body radiotherapy for treating difficult lung, liver and pancreatic lesions. Dr. McDonald joined Salem’s Radiation Therapy Consultants in March 2010.
Cancer care coordinators

Our cancer care coordinators are certified oncology nurses with 45 years of combined experience. Care coordinators are a dedicated member of the cancer care team and provide ongoing support throughout treatment: meeting with patients and families to identify needs, problem-solve, and provide resources and information.

Certified breast care nurse

Our certified breast care nurse provides invaluable resources and guidance as patients begin their breast cancer journey. As a two-time breast cancer survivor, she can offer a unique perspective to women battling cancer.

Cancer rehabilitation program

Our physical therapy team includes a certified cancer exercise specialist and a lymphedema specialist; together, they create customized programs to help patients cope with treatment-related side effects.

Dedicated oncology licensed clinical social worker

Our licensed clinical social worker provides counseling and coping strategies to help patients and families manage the emotional aspects of cancer diagnosis, treatment and survivorship.

Integrated inpatient oncology unit

Beginning in 2011, inpatient care has been consolidated in a 30-bed, medical-surgical telemetry unit. Our inpatient oncology team includes 21 oncology certified nurses, two hospice and palliative care nurses, and two medical-surgical certified nurses – all dedicated to delivering comprehensive care throughout a patient’s stay.

Oncology certified dietitian

Salem health has one of the few oncology certified dietitians in Oregon, helping patients manage treatment effects and optimize recovery.

Palliative care services

By physician referral, we work with attending physicians, patients and families to relieve and reduce pain, and to increase comfort – both physically and psychologically – for patients with any life-limiting disease. We use a multi-disciplinary approach that includes physician consultations, along with palliative care nurse, chaplain, social worker and dietitian.

Peer navigator program

Salem Cancer Institute has more than 20 cancer survivors trained as peer navigators. These volunteers share their experiences and provide support and guidance for patients facing a new diagnosis or undergoing treatment.

Support and education for patients and families

We offer a wide variety of support groups and educational opportunities for people living with cancer and for those who love and support them:

- Cancer Support Group
- Caregiver Support Group
- Head & Neck Cancer Support Group
- Prostate Cancer Support Group
- Women’s Metastatic Support Group
- Knit Well Support Group
- Starting Chemotherapy class
- Yoga class

ATTRACTION TOP SPECIALISTS | Medical Oncology

John Strother, M.D.

Dr. Strother, a medical oncologist, is the affiliation medical director of the Salem Cancer Institute and OHSU Knight Cancer Institute collaboration. He received his medical degree from Penn State College of Medicine and completed his residency in internal medicine at OHSU, where he received fellowship training in hematology and medical oncology. Dr. Strother joined Hematology Oncology of Salem in April 2008. He is board certified in internal medicine, hematology and medical oncology.
Community outreach

Education and awareness
Salem Cancer Institute is committed to prevention, screening and education through community outreach.

In 2010, we organized and participated in numerous activities to promote awareness in our community. Here are just a few examples:

• A featured one-day event, Targeting Cancer with Education and Awareness. The event offered classes on breast health, genetic counseling, dispelling cancer myths, and healthy living through nutrition and exercise.
• Local events including Play for a Cure Oregon, a softball tournament for breast cancer; the Salem Relay for Life and the Discover Pink Walk.
• Various cancer awareness nights as part of high school and Chemeketa Community College volleyball games.
• Shine a Light on Lung Cancer event with Bud Pierce, M.D., as our speaker.
• Colon cancer screening in partnership with Salem Gastroenterology Consultants and Pacific Pathology.
• Skin cancer screening with our partner, Dermatology Clinic, P.C.

The results of cancer screening led to treatment for some community members who were uninsured and would not have been screened otherwise.

Working with national and community partners
The following community partners have worked with us over the past year to support our mission of providing the highest quality, patient-centered cancer care to our region:

American Cancer Society
Salem-Keizer Volcanoes Baseball
Community Health Education Center at Salem Hospital
Salem Gastroenterology Consultants
Leukemia & Lymphoma Society
Dermatology Clinic, P.C.
Linda L. Vladyka Breast Wellness Foundation
National Lung Cancer Alliance
– Play for a Cure Oregon
Susan G. Komen for the Cure – Oregon & SW Washington Affiliate
YWCA Salem
Go Downtown Salem
Chemo Bags Filled with Love, Inc.

Medical Foundation of Marion and Polk Counties
Since April 2009, volunteer physicians, hospitals and other healthcare professionals in the mid-Willamette Valley have offered free healthcare services to uninsured community residents through Project Access, a program supported by the Medical Foundation of Marion and Polk Counties. Salem Cancer Institute is proud to participate as part of its mission to provide high-quality oncology care for the community.

In its first year, Project Access provided free healthcare valued at $6 million to 474 people. In 2010, the estimated value of donated services was $10 million.

Prescription medications offered through MedAssist
Salem Cancer Institute also supports MedAssist, a program of the Medical Foundation of Marion and Polk Counties, which was created in 2001. MedAssist provides uninsured residents of Marion and Polk counties with free monthly access to prescription medications. In 2010, MedAssist provided over $2 million worth of prescriptions.

The Salem Hospital Foundation
Through The Salem Hospital Foundation, many generous donors in the Willamette Valley contributed to Salem Cancer Institute. One example is $1.3 million of the $4.8 million needed to invest in the Trilogy linear accelerator with RapidArc technology in 2010.

“Our goal is to help the Institute continue offering cancer patients the best treatment possible,” said Kelly Yunker, chair of The Salem Hospital Foundation board.

Additional Foundation support includes $85,000 for Salem Cancer Institute’s palliative care program, launched in October 2009, with more than 300 patients seen through the end of 2010. Contributions of $40,000 provided ongoing support for Salem Cancer Institute programs, including patient transportation, the prescription assistance fund, a yoga instructor and SOFTEE® recovery camisoles for women recovering from breast cancer treatment.

Philanthropic support for special projects at Salem Cancer Institute provided patient education booklets on lymphedema and arm care after breast cancer treatment. It also provides breast care kits.

A journey of giving
Lynetta Kirsch is a four-year cancer survivor, diagnosed with Stage II breast cancer in 2007. Her husband, Kevin, helped Lynetta get through chemotherapy by packing a bag for her before every session. The bags contained Lynetta’s favorite items to help her get through each session—books, magazines, chocolate and more.

When she completed her journey, Lynetta decided to help others by founding Chemo Bags Filled with Love, dedicated to bringing comfort to other chemo patients. Community members donate items to the nonprofit organization, which provides them to patients through Salem Cancer Institute. Lynetta is also a peer navigator for Salem Cancer Institute.
Salem Cancer Registry: improving treatments and outcomes since 1960

At Salem Cancer Institute, we are committed to improving the future of cancer care by learning from the past. The Salem Cancer Registry is among the oldest in the United States. Established in 1960, it includes data from more than 54,000 cases.

In 2009, the registry added 1,834 cases which have utilized the services of Salem Cancer Institute. Registry data allows physicians, researchers and public health professionals to track disease, and treatment trends and efficacy.

The Cancer Registry captures history, diagnosis, treatment and disease status data for patients with all types of cancer in Salem Health’s defined population. This includes patients treated at Salem Cancer Institute, West Valley Hospital, Silverton Hospital, Santiam Hospital and local outpatient facilities.

Physicians use Cancer Registry information to improve treatment planning, staging and continuity of care. Information on efficacy and outcomes also helps our oncology teams introduce new treatment technologies.

The Cancer Registry is staffed by certified tumor registrars, an essential part of the Salem Cancer Institute care team. In addition to collecting and reporting data, the Cancer Registry provides data on patient survival, treatment and extent of disease to track disease, and treatment trends and efficacy.

In 2009, the registry added 1,834 cases which have utilized the services of Salem Cancer Institute. Registry data allows physicians, researchers and public health professionals to track disease, and treatment trends and efficacy.

Our physician cancer care teams

Our physicians are committed to providing coordinated oncology care for each patient. They work closely with referring providers to ensure the best clinical outcomes. Every physician at Salem Hospital is board certified or board eligible and will be certified within five years of initial appointment.

Cardiothoracic
Kai Engstad, M.D.

Gastroenterology
Richard Brandes, M.D.
Michael Buck, M.D.
Makkallearn Em, M.D.
Lawrence Gates Jr., M.D.
Katherine Hoda, M.D.
Patrick Kao, M.D.
Robert Ponec, M.D.
Gregory Potter, M.D.
Edward Schultheiss, M.D.
Christian Speer, M.D.

General Surgery
Catherine Boulay, M.D.
Glena Caton, m.D.
Andrew Clarke, M.D.
Gary Nishioka, m.D.
Jennifer Neahring, m.D.
Gary Jones, M.D.
Gary Mann, M.D.
David Harrison, M.D.

Medical Oncology
Edward Orlovski, M.D.
Charles Petrunin, M.D.
William Pierce, M.D.
John Stritcher, M.D.
Natalia Tiffany, M.D.

Neurosurgery
Magdalena Banasiak, M.D.
Robert Buza, M.D.
Maurice Collada, M.D.
Judy Hubbard, M.D.
Julie York, M.D.

Otolaryngology
Joseph Allen, M.D.
John Donovan, M.D.
Bruce Johnson, M.D.
Gary Nishikia, M.D.
Douglas Skarada, M.D.
Clark Thompson, M.D.

Oncology Medicine
Edward Austin, M.D.
Bruce Carter, M.D.
Dann Leonard, M.D.
William Nisbet, M.D.

Pulmonary Medicine
Fayez Bader, M.D.
Kamran Firoozii, M.D.
Sahel Histall, M.D.
Martyn Johnson II, M.D.
Steven Marvel, M.D.
James Parosa, M.D.
Theodore Shultz, M.D.

Radiation Oncology
Matthew Gordon, M.D.
Ariella Hening, M.D.
Matthew Kang, M.D.
Tasha McDonald, M.D.
Nancy Reyes-Molyneux, M.D.
Theodore Williamson, M.D.

Salem Cancer Institute
2009 Cancer Registry

<table>
<thead>
<tr>
<th>Primary Site</th>
<th># of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td>67</td>
</tr>
<tr>
<td>Brain/Ochs</td>
<td>47</td>
</tr>
<tr>
<td>Breast</td>
<td>316</td>
</tr>
<tr>
<td>Cervix/Uteri</td>
<td>8</td>
</tr>
<tr>
<td>Colon</td>
<td>94</td>
</tr>
<tr>
<td>Connective/Sarcoma</td>
<td>7</td>
</tr>
<tr>
<td>Corpus Uteri</td>
<td>35</td>
</tr>
<tr>
<td>Esophagus</td>
<td>22</td>
</tr>
<tr>
<td>Kidney/Ureter</td>
<td>60</td>
</tr>
<tr>
<td>Leukemia</td>
<td>42</td>
</tr>
<tr>
<td>Liver/Biliary</td>
<td>17</td>
</tr>
<tr>
<td>Lung</td>
<td>224</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>83</td>
</tr>
<tr>
<td>Melanoma</td>
<td>78</td>
</tr>
<tr>
<td>Myeloma</td>
<td>35</td>
</tr>
<tr>
<td>Oral/Head and Neck</td>
<td>47</td>
</tr>
<tr>
<td>Ovary</td>
<td>20</td>
</tr>
<tr>
<td>Pancreas</td>
<td>21</td>
</tr>
<tr>
<td>Prostate</td>
<td>203</td>
</tr>
<tr>
<td>Rectum</td>
<td>14</td>
</tr>
<tr>
<td>Stomach</td>
<td>22</td>
</tr>
<tr>
<td>Testis</td>
<td>9</td>
</tr>
<tr>
<td>Thyroid</td>
<td>30</td>
</tr>
<tr>
<td>Other/Undefined</td>
<td>217</td>
</tr>
<tr>
<td>Total</td>
<td>1,834</td>
</tr>
</tbody>
</table>
Salem Cancer Institute is part of Salem Health, which includes Salem Hospital, West Valley Hospital, Willamette Health Partners and other affiliated health care organizations offering quality care to people in and around Oregon’s mid-Willamette Valley.